Masimo delivered strong results in the second quarter of 2025, with GAAP revenue reaching $371 million and non-GAAP diluted EPS growing 46% to $1.33. The company's core healthcare business demonstrated robust growth and earnings, supported by effective tariff mitigation measures.
GAAP revenue for Q2 2025 was $371 million, an 8% increase year-over-year.
Non-GAAP net income per diluted share was $1.33, representing a 46% growth compared to the prior year period.
The company's core healthcare business showed strong growth and earnings.
Masimo successfully implemented tariff mitigation measures, reducing the tariff impact by 50% from original estimates.
Masimo updated its full-year 2025 guidance for continuing operations, reflecting strong non-GAAP revenue growth and improved operating profit and EPS, even with the impact of new tariffs.